CYP2C9

Cytochrome P450 2C9 · P11712 · CYP2C9 on Sugi Atlas →

2,266,711 patent compounds predicted against CYP2C9, 1,444,617 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fluconazole (SCHEMBL3151)	1.00	12/20
Warfarin (SCHEMBL3689)	1.00	10/20
Ergotamine (SCHEMBL1483)	0.84	8/20
Miconazole (SCHEMBL2866)	1.00	7/20
(R)-Miconazole (SCHEMBL2867)	1.00	7/20
Miconazole (SCHEMBL3366)	0.98	7/20
(R)-Miconazole (SCHEMBL3367)	0.98	7/20
Nifedipine (SCHEMBL3968)	1.00	5/20
Medrysone (SCHEMBL4493)	1.00	5/20
Omeprazole (SCHEMBL1192)	0.60	5/20
SCHEMBL2386	1.00	4/20
Fluvastatin (SCHEMBL2846)	1.00	4/20
Fluvastatin (SCHEMBL2847)	1.00	4/20
Fluvastatin (SCHEMBL2848)	1.00	4/20
Fluvastatin (SCHEMBL2849)	1.00	4/20
Noscapine (SCHEMBL4559)	1.00	4/20
Butylated Hydroxytoluene (SCHEMBL3950)	0.65	4/20
Cyclandelate (SCHEMBL5123)	0.57	4/20
Pitavastatin (SCHEMBL3369)	0.54	4/20
Pentachlorophenol (SCHEMBL1492)	0.53	4/20

Clinical trials — most relevant to CYP2C9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes	PHASE4	COMPLETED
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole	PHASE4	COMPLETED
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome	PHASE4	COMPLETED
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer	PHASE2	RECRUITING
A Study of TY-1091 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	UNKNOWN
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans	PHASE2	COMPLETED
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib	PHASE2	COMPLETED
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer	PHASE2	COMPLETED
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients	PHASE1	COMPLETED
A Study to Evaluate the Effect of Genotype on LY2216684	PHASE1	COMPLETED
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer	PHASE1	COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors	PHASE1	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings	nan	COMPLETED
Cannabidiol for Pediatric Epilepsy (Compassionate Use)	nan	NO_LONGER_AVAILABLE
Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System Reinforced With Patient Specific Pharmacogenetic Data for Minimizing Severe Drug-Drug Interactions	nan	COMPLETED
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke	nan	COMPLETED
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information	nan	COMPLETED
CYP2C19 Variants and Limonene Metabolism	nan	RECRUITING
The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia	nan	ACTIVE_NOT_RECRUITING
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients	nan	COMPLETED
Voriconazole Blood Levels and Toxicity	nan	COMPLETED
Genotype-Guided Warfarin Therapy Trial	nan	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2C9 binder may also engage these)

Protein	Name	Similarity
Q08078	—	0.999	Q08078 →
Q64458	—	0.999	Q64458 →
P33263	—	0.999	P33263 →
P56656	—	0.998	P56656 →
P33264	—	0.998	P33264 →
CYP2C19	Cytochrome P450 2C19	0.998	landscape →
P05179	—	0.997	P05179 →
P15123	—	0.996	P15123 →
CYP2C8	Cytochrome P450 2C8	0.996	landscape →
P00181	—	0.995	P00181 →
P33265	—	0.994	P33265 →
P56654	—	0.994	P56654 →
E9Q5K4	—	0.993	E9Q5K4 →
Q64583	—	0.993	Q64583 →
P08683	—	0.993	P08683 →
P33262	—	0.993	P33262 →
P17666	—	0.993	P17666 →
P00180	—	0.992	P00180 →
P33273	—	0.992	P33273 →
P00179	—	0.991	P00179 →
P05178	—	0.990	P05178 →
P24470	—	0.990	P24470 →
CYP2A7	Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7)	0.990	landscape →
P56655	—	0.989	P56655 →
P20812	—	0.989	P20812 →
Q9D816	—	0.988	Q9D816 →
P12790	—	0.988	P12790 →
Q6XVG2	—	0.988	Q6XVG2 →
P33272	—	0.988	P33272 →
Q91X77	—	0.988	Q91X77 →